Table 1.

Summary of mice injected with AAV-TeLC or with AAV-GFP, the anatomical distribution of TeLC expression, and the total number of seizures observed

No.	Injection: AAV-FLEX-	Sub/CA1	CA3	PrS	PaS	DG	EC	C-SWD	Number of seizures	Days recorded
Group 1: AAV-FLEX-TeLC injected, no seizures
1	TeLC	++	+	++	++	+	++	−	0	28
2	TeLC	++	+					−	0	32
3	TeLC	+++					++	−	0	48
4	TeLC	+++	+	++	+++	++	++	+	0	55
5	TeLC	+++	+++	+	++	+++		+	0	56
6	TeLC	++						+	0	48
7	TeLC	++						+	0	55
8	TeLC	+++	++	++	+++	+++	++	+	0	56
9	TeLC	++		+	++		+	+	0	55
Group 2: AAV-FLEX-TeLC injected, with seizures
10	TeLC	+++			+		+	+	1	35
11	TeLC	++	+	++	++	++		+	3	56
12	TeLC	+++		+	+++	+	+	+	19	47
13	TeLC	++	++	+++	+++	++		+	5	30
14	TeLC	+++	+					+	2	47
15	TeLC	+++	+				++	+	5	47
16	TeLC	+++					+	+	2	18
17	TeLC	+++	+	+		+		+	6	32
18	TeLC	+++	+	++	+++	+++		+	12	56
19	TeLC	++					++	+	9	30
20	TeLC	+++		+	+			+	9	40
21	TeLC	++			+			+	6	30
22	TeLC	+++		+	++			+	9	25
23	TeLC	++						+	2	38
24	TeLC	++						+	5	28
25	TeLC	+++		+	++			+	7	34
Group 3: AAV-FLEX-GFP injected
26	GFP	++			+		+++	−	0	56
27	GFP	++	+	+	+++	+++	+++	−	0	55
28	GFP	+++		++	+++	+	+	−	0	47
29	GFP	n.e.						−	0	55
30	GFP	n.e.						−	0	43
31	GFP	+++	++	+++	+++	++	++	−	0	57
32	GFP	++						−	0	54
33	GFP	++		+				−	0	52
34	GFP	++	++	++	+++	++	+	−	0	52
Group 4: AAV-FLEX-TeLC injected and 10 d later with PTZ
35	TeLC + PTZ	++		+				+	14	28
36	TeLC + PTZ	++						+	6	53
37	TeLC + PTZ	++		+	+			+	43 se	34
38	TeLC + PTZ	++		+				+	9	53
39	TeLC + PTZ	++						+	9	52
40	TeLC + PTZ	++		+				+	7	52

Injections were performed unilaterally into the ventral subiculum, and mice were subjected to telemetric EEG and video monitoring. Group 1 (1–9), Mice that revealed no spontaneous seizures, but (except 1–3) C-SWDs. Six of these mice (4–9) that had experienced C-SWDs but were seizure free at day 42 (Fig. 3) were then injected with a threshold dose of PTZ resulting in acute and then recurrent spontaneous seizures (Fig. 6). Group 2 (10–25), 16 of 25 AAV-TeLC-injected mice (10–25) revealed spontaneous recurrent seizures and C-SWDs. Group 3 (26–34), none of nine AAV-GFP-injected mice exhibited recurrent seizures and were considered as controls. The fact that these mice also did not present C-SWDs argues against an unspecific effect of vector injection. Group 4 (35–40), these mice were injected with AAV-TeLC and after 10 d with PTZ. They were seizure free after AAV-TeLC injection but exhibited acute and then spontaneous recurrent C-SWDs and seizures after PTZ injection. Mouse 37 died from a status epilepticus on day 34. Expression of GFP (tag for AAV-TeLC) was most prominent in the subiculum/sector CA1, often extending to the presubiculum and parasubiculum, and, in some instances to the entorhinal cortex or to the dentate gyrus. se, Status epilepticus; PrS, presubiculum; PaS, parasubiculum; EC, entorhinal cortex; DG, dentate gyrus; n.e., not evaluated.